Sarepta Therapeutics, Inc. (SRPT) Ownership
SRPT ownership summary
as of October 18, 2026- Institutions
- 103.4% of shares outstanding
- Insiders
- 4.88% of shares outstanding
- Shares outstanding
- 105.6M
- Float
- 100.5M shares available to trade
- Short interest
- 25.85% 22.8M shares short
- Days to cover
- 7.77 short interest down 10.4% vs prior month
- Institutions 103.41%
- Insiders 4.88%
SRPT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 17.98% | 19.0M | $324.8M | +4.2M (+28.7%) | June 30, 2026 |
| 2 | State Street Corp | 8.44% | 8.9M | $152.5M | +2.3M (+34.8%) | June 30, 2026 |
| 3 | Vanguard Portfolio Management, LLC | 7.93% | 8.4M | $143.3M | +1.7M (+26.2%) | June 30, 2026 |
| 4 | Two Sigma Investments LLC | 4.35% | 4.6M | $78.6M | +5,540 (+0.1%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 4.35% | 4.6M | $78.5M | +13,520 (+0.3%) | June 30, 2026 |
| 6 | First Trust Advisors L.P. | 4.13% | 4.4M | $74.7M | +230,163 (+5.6%) | June 30, 2026 |
| 7 | AQR Capital Management LLC | 4.10% | 4.3M | $74.0M | −2.1M (−32.8%) | June 30, 2026 |
| 8 | Geode Capital Management, LLC | 2.62% | 2.8M | $47.4M | +782,962 (+39.4%) | June 30, 2026 |
| 9 | Erste Asset Management GmbH | 2.43% | 2.6M | $43.9M | −400,000 (−13.5%) | June 30, 2026 |
| 10 | Marshall Wace Asset Management Ltd | 2.09% | 2.2M | $37.7M | +1.5M (+204.3%) | June 30, 2026 |
| 11 | Morgan Stanley - Brokerage Accounts | 2.09% | 2.2M | $37.7M | −394,352 (−15.2%) | June 30, 2026 |
| 12 | Aberdeen Group PLC | 2.08% | 2.2M | $37.5M | −123,942 (−5.3%) | June 30, 2026 |
| 13 | Bank of America Corp | 1.95% | 2.1M | $35.2M | −89,941 (−4.2%) | June 30, 2026 |
| 14 | The Goldman Sachs Group Inc | 1.93% | 2.0M | $34.9M | +964,249 (+89.4%) | June 30, 2026 |
| 15 | UBS Group AG | 1.54% | 1.6M | $27.8M | −608,044 (−27.2%) | June 30, 2026 |
| 16 | Federated Hermes Inc | 1.51% | 1.6M | $27.2M | −195,690 (−11.0%) | June 30, 2026 |
| 17 | Northern Trust Corp | 1.15% | 1.2M | $20.7M | +486,473 (+67.2%) | June 30, 2026 |
| 18 | Millennium Management LLC | 1.13% | 1.2M | $20.4M | −28,214 (−2.3%) | June 30, 2026 |
| 19 | T. Rowe Price Investment Management,Inc. | 1.09% | 1.2M | $19.8M | +22,775 (+2.0%) | June 30, 2026 |
| 20 | Citigroup Inc | 1.09% | 1.2M | $19.8M | +7,358 (+0.6%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 12.3M shares and 8 cut 3.9M.
SRPT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | iShares Core S&P Small-Cap ETF | 5.95% | 6.3M | $107.5M | +1,548 (+0.0%) | September 30, 2026 |
| 2 | First Trust NYSE Arca Biotech ETF | 4.52% | 4.8M | $81.7M | — | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 3.02% | 3.2M | $54.6M | +1,878 (+0.1%) | August 31, 2026 |
| 4 | State Street® SPDR® S&P® Biotech ETF | 2.82% | 3.0M | $50.9M | −56,950 (−1.9%) | September 30, 2026 |
| 5 | iShares Russell 2000 ETF | 2.55% | 2.7M | $46.0M | −31,040 (−1.1%) | September 30, 2026 |
| 6 | Vanguard Small Cap Index | 2.14% | 2.3M | $38.6M | −46,204 (−2.0%) | September 30, 2026 |
| 7 | Vanguard MStar Small Cap Growth Indx Inv | 1.19% | 1.3M | $21.5M | −63,234 (−4.8%) | September 30, 2026 |
| 8 | Fidelity Small Cap Index | 1.08% | 1.1M | $19.5M | +9,556 (+0.8%) | July 31, 2026 |
| 9 | Federated Hermes MDT Mid Cap Growth A | 1.05% | 1.1M | $18.9M | −87,155 (−7.3%) | June 30, 2026 |
| 10 | Vanguard Strategic Equity Inv | 0.92% | 973K | $16.6M | +391,284 (+67.3%) | June 30, 2026 |
| 11 | State Street SPDR Port S&P 600 Sm CpETF | 0.91% | 958K | $16.4M | — | September 30, 2026 |
| 12 | iShares Russell 2000 Value ETF | 0.86% | 906K | $15.5M | +1,374 (+0.2%) | September 30, 2026 |
| 13 | iShares Biotechnology ETF | 0.75% | 788K | $13.5M | −5,968 (−0.8%) | September 30, 2026 |
| 14 | Vanguard Tax-Managed Small Cap Adm | 0.66% | 700K | $12.0M | — | September 30, 2026 |
| 15 | Invesco Biotechnology & Genome ETF | 0.59% | 620K | $10.6M | — | September 30, 2026 |
| 16 | Vanguard Russell 2000 ETF | 0.57% | 605K | $10.3M | +7,000 (+1.2%) | September 30, 2026 |
| 17 | iShares S&P Small-Cap 600 Growth ETF | 0.57% | 597K | $10.2M | — | September 30, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.53% | 556K | $9.5M | +369 (+0.1%) | September 30, 2026 |
| 19 | Vanguard Explorer Inv | 0.50% | 529K | $9.0M | +199,398 (+60.6%) | June 30, 2026 |
| 20 | Fidelity Extended Market Index | 0.49% | 521K | $8.9M | +83,663 (+19.1%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
SRPT insider transactions
latest 2| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | Stephen Mayo | Sell | $17.02 | 7,239 | $123,208 |
| 2025-12-16 | Ian Michael Estepan | Sell | $22.31 | 13,187 | $294,202 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
SRPT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns SRPT
Institutional investors own 103.4% of Sarepta Therapeutics's shares and insiders 4.88%. The largest holder is BlackRock Inc with 17.98% of the shares (19.0M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 8 reduced their stake in the latest filings. Short interest is 25.85% of the float, or 7.77 days of average trading volume. The share count rose 153.7% since 2014.
Related: SRPT analyst forecast, SRPT key metrics. See the SRPT stock overview for the latest quote and news.
SRPT ownership FAQ
Who owns the most Sarepta Therapeutics stock?
The largest shareholders of Sarepta Therapeutics are BlackRock Inc (17.98%), State Street Corp (8.44%), Vanguard Portfolio Management, LLC (7.93%), Two Sigma Investments LLC (4.35%), Vanguard Capital Management, LLC (4.35%).
What percentage of Sarepta Therapeutics is owned by institutions?
Institutions hold 103.4% of Sarepta Therapeutics's shares outstanding; insiders hold 4.88%.
Which funds own Sarepta Therapeutics?
The largest fund holders of Sarepta Therapeutics are iShares Core S&P Small-Cap ETF (5.95%), First Trust NYSE Arca Biotech ETF (4.52%), Vanguard MStar Total Stk Mkt Idx Invest (3.02%), State Street® SPDR® S&P® Biotech ETF (2.82%), iShares Russell 2000 ETF (2.55%).
What is Sarepta Therapeutics's short interest?
22.8M shares of Sarepta Therapeutics were sold short, 25.85% of the float; at the average daily volume it would take 7.77 days to cover.
Are insiders buying or selling Sarepta Therapeutics?
Of the latest 2 reported insider transactions in Sarepta Therapeutics (since December 16, 2025), 0 were purchases and 2 were sales.
How many shares of Sarepta Therapeutics are outstanding?
Sarepta Therapeutics has 105.6M shares outstanding, of which 100.5M are in the public float.